Dr. Paul Sax makes the case for intravenous remdesivir for COVID-19 in
HIV and ID Observations.
In the PINETREE study, high-risk outpatients treated with remdesivir had an 87% reduction in the risk for hospitalization or death from severe COVID-19. With the arrival of the Omicron variant, says Dr. Paul Sax in the latest HIV and ID Observations, these results instantly become relevant.
Do you want to be notified whenever Dr. Sax posts? Sign up to receive notifications by email by using the Subscribe box.
Want to see more from NEJM Journal Watch? Register here.